Clever Leaves to take advantage of the export authorization

  • The export of dried cannabis flowers from Colombia was authorized by a new decree signed on July 23rd, 2021, at the Clever Leaves cultivation facility by President Ivan Duque and his ministers.
  • With flowers accounting for around 50% of the global medical cannabis markets, this decree doubles the total addressable market for Clever Leaves’ Colombian operations.1
  • The Colombian operation of Clever Leaves is well positioned to take advantage of this change, given its 1.8 million square feet of cultivation, Latin America’s only CUMCS GACP and EUGMP certifications for dried flower production.
  • Clever Leaves will now be able to offer its customers a full portfolio of cannabinoid options with its extracts, isolates and floral products from Colombia and its floral products from Portugal.
  • As a trusted B2B partner, Clever Leaves can now leverage its global partnerships to deliver high quality, innovative floral products for the benefit of patients around the world.

NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) – Clever Leaves Holdings Inc. (Nasdaq: CLVR) (“Clever Leaves” or the “Company”), a multinational operator and licensed producer of pharmaceutical grade cannabinoids, welcomed the Chairman Colombian Duque at his grow plant in Colombia for the signing of a new decree that allows Colombian licensed cannabis companies such as Clever Leaves to participate in the commercial production and export of medical cannabis flowers. With flowers accounting for around 50% of the global medical cannabis markets, this decree doubles the total addressable market for Colombian cannabis producers.

Clever Leaves is well positioned to take advantage of this opportunity to export dried cannabis flowers, leveraging its 1.8 million square foot CUMCS GACP certified grow facility, EUGMP Part II certification covering flower production dried and over 30 cannabinoids. genetics registered in the country. Colombia’s environmental conditions, coupled with Clever Leaves’ experience in the sustainable cultivation of cannabis, will allow the company to bring unique pharmaceutical grade products to market. The Colombian flower complements Clever Leaves’ already strong Portuguese flower production, allowing the company to present a comprehensive portfolio, covering different strains and growing conditions, that will meet the ever-changing needs of patients.

Having shipped cannabis products to more than 15 countries on five continents, Clever Leaves has a strong network of partners globally, who will benefit from its broader flower offering. Clever Leaves will leverage its position as a trusted B2B partner to develop and produce innovative, high-quality products for medical cannabis patients around the world.

This regulatory change, allowing the export of dried flowers, will catalyze the continued development of the Colombian medical cannabis industry by removing the restriction that blocked access to 50% of the global medical cannabis market. In addition, the decree includes features that will help Clever Leaves drive further growth, including streamlined processes in quota management systems, which enable efficiencies and improve Clever Leaves’ ability to serve customers faster. . The bill also includes access to medical cannabis for patients in Colombia.

During the visit to the Clever Leaves facilities, President Duque, who was accompanied by several of his ministers, regional and local authorities, underlined the expected impact of this for the country: “This new decree represents an important step for the Colombia, allowing us to compete in international markets. In addition, the decree raises the standards of our products and brings significant added value, particularly in the medical field. Clever Leaves has served as a benchmark for the Colombian cannabis industry, generating 17 jobs per hectare at its grow plant. I encourage our government representatives from various entities to unite and further support the development of the industry.

Kyle Detwiler, CEO of Clever Leaves said: “The Colombian government’s policy change could double our addressable market of Colombia, a region where Clever Leaves has made a substantial capacity investment but where we have been limited to selling only products. processed or extracted. up to that point in time. Nevertheless, since 2016, we have been developing the necessary capacities to produce a pharmaceutical grade product.

“This regulatory evolution will allow us to better serve our customers around the world by capitalizing on the only EU GMP certified cannabis farm in Latin America, which to many people’s surprise already includes EU certified dry flower production. GMP. Hoping to anticipate this moment, our team has spent the last few years developing business relationships, market knowledge and sourcing partnerships on a global scale, and this catalyst will hopefully unleash a potential important to our gradually expanding customer base. Through our Portuguese dry flower production facility, we have learned and successfully overcome the various challenges facing a floral operation, including quality requirements, GACP and EU GMP certifications, sterility protocols, logistics of import / export of psychoactive products and the potency requirements of cannabinoids different from that of processed or extracted products. We hope that these lessons and relationships will allow Clever Leaves to take advantage of Colombia’s new cannabis regulations.

___________________________________
1
Market size estimates calculated from data reported in:

  1. Grandview Industry Analysis, Legal Marijuana Market Size Share and Trend Analysis Report by Marijuana Type (Medical, Adult), Product Type (Flower, Oil), by Medical Application (chronic pain, mental disorders) and segment forecast, 2021 – 2028. May 2021
  2. BDS Analytics, Arcview Market Research, The State of Legal Cannabis Markets, 7e Edition, update 2020.

About Clever Leaves Holdings Inc.

Clever Leaves is a multinational cannabis company that emphasizes large-scale, ecologically sustainable cultivation and pharmaceutical grade processing as the cornerstones of its global cannabis business. With operations and investments in the United States, Canada, Colombia, Germany and Portugal, Clever Leaves has created an efficient distribution network and global presence, with a foundation built on capital efficiency and growth. quick. Clever Leaves aims to be one of the industry’s leading global cannabis companies, recognized for its principles, people and performance while fostering a healthier global community. Clever Leaves has received several international certifications which have enabled it to increase its export and sales capacity from its Colombian operations, including the European Union Good Manufacturing Practices (EU GMP) certification, a certification of Good Manufacturing Practices (GMP) from Colombia’s National Food and Drug Surveillance. Institute – Invima Certification and Good Agricultural and Collecting Practices (GACP). Clever Leaves has obtained a license in Portugal from Infarmed – the Portuguese health authority – which allows Clever Leaves to grow, import and export dry flowers for medicinal and research purposes. In addition, the Portuguese operation has obtained certification of compliance with GACP and IMC-GAP standards.

For more information, please visit https://cleverleaves.com/en/home/ and follow us on LinkedIn.

Clever leaves investor demands:
Cody Slach and Jackie Keshner
Investor Relations Gateway
+ 1-949-574-3860
[email protected]

Clever Leaves press contacts:
Mckenna miller
KCSA strategic communication
+ 1-347-487-6197
[email protected]

Diana Siguenza
Director of Strategic Communication
+ 57-310-236-8830
[email protected]

Clever Leaves business inquiries:
Andrew Miller
Vice President of Sales – EMEA, North America and Asia-Pacific
+ 1-416-817-1336
[email protected]


Source link

More Stories
How COVID-19 is Affecting Natural Language Processing (NLP) Growth in Healthcare and Life Sciences Market – The Manomet Current